| Authors: |
Sutton VR; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Watt SV; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Akhlaghi H; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Cipolla DC; Insmed Incorporated, Bridgewater, NJ, United States., Chen KJ; Insmed Incorporated, Bridgewater, NJ, United States., LaSala D; Insmed Incorporated, Bridgewater, NJ, United States., McDonald PP; Insmed Incorporated, Bridgewater, NJ, United States., Beavis PA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Munoz I; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Hodel AW; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Noori T; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Voskoboinik I; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Trapani JA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia. |
